Oral MS drug Gilenya has yet to show ‘full potential'
Oral MS drug Gilenya has yet to show ‘full potential'
Novartis's multiple sclerosis pill Gilenya, which faces a threat from a rival product under development by Biogen Idec Inc, has yet to show its full potential, the Swiss drugmaker’s head of development said.
Gilenya, approved by U.S. regulators last year as the first pill against relapsing forms of multiple sclerosis, may also work in patients with a more severe form of the disease called primary progressive, Novartis’s Trevor Mundel said yesterday in a telephone interview. “We haven’t seen the full potential with Gilenya,” according to Mundel.... Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/1309
MS-UK - http://www.ms-uk.org/
-
- Similar Topics
- Replies
- Views
- Last post
-
- 0 Replies
- 2534 Views
-
Last post by NHE
-
- 1 Replies
- 1056 Views
-
Last post by Petr75
-
- 5 Replies
- 13074 Views
-
Last post by gibbledygook
-
- 0 Replies
- 449 Views
-
Last post by NHE
-
- 0 Replies
- 1416 Views
-
Last post by NHE
-
- 1 Replies
- 2883 Views
-
Last post by Tif
-
- 2 Replies
- 842 Views
-
Last post by DIM
-
- 1 Replies
- 1763 Views
-
Last post by raceya